Lilly, AZ, AbbVie and J&J are among the drugmakers who stand to lose the most product revenue from proposed legislation that would allow Medicare to negotiate prices.
Robert Zirkelbach, public affairs EVP at PhRMA, discussed the group’s legislative priorities at the Coalition for Healthcare Communication’s post-election conference on Tuesday.